Penn Memory Center Co-Directors Jason Karlawish, MD, and David Wolk, MD, each addressed the role of biomarkers in Alzheimer’s research during this year’s Alzheimer’s Association International Conference (AAIC) in London.
The annual conference brings together 5,000 researchers to network and discuss their research, findings, and theories in relation to Alzheimer’s disease, dementia, and other types of cognitive impairment.
David Wolk, MD
Wolk was executive committee chairman of the Alzheimer’s Imaging Consortium (AIC), an AAIC preconference focused on the clinical application and methodological development of neuroimaging to Alzheimer’s disease, other dementias, and normal brain aging.
Jason Karlawish, MD
Karlawish addressed a crowd of more than 300 attendees at AIC, describing PMC research on the “ethics and consequences of biomarker disclosure.”
Wolk also spoke during a satellite symposium called “Biomarkers in the Dementia Spectrum: Moving the Field to an Etiological Diagnosis. His talk was titled “Use of Biomarker Combinations to Assess Change in Cognitive Status over Time.”
The 2018 AAIC conference will take place in Chicago, Illinois.